Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors

Current Opinion in Investigational Drugs

Volumn 3, Issue 4, 2002, Pages 627-633

  Aparicio, Ana ^a   Weber, Jeffrey S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

5 Aza 2 deoxycytidine; 5 Azacytidine; Clinical trials; DNA methylation; Solid tumor

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANTIEMETIC AGENT; AZACITIDINE; CISPLATIN; DNA; HISTONE DEACETYLASE INHIBITOR; PIRAZOFURIN; TOPOTECAN; TRICHOSTATIN A; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; HEMATOLOGIC AGENT;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CARCINOGENESIS; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DNA METHYLATION; DOSE RESPONSE; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE EXPRESSION REGULATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN GENOME; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; NAUSEA AND VOMITING; NEOPLASM; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS; DNA METHYLATION; HEMATOLOGIC AGENTS; HEMATOLOGIC DISEASES; HUMAN; NEOPLASMS; HUMANS;

EID: 0035988868     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. DNA methylation and gene function
2. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes
3. Mutation hotspots and DNA methylation
4. Cancer epigenetics comes of age
5. DNA methylation in early development
6. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon
7. DNA hypomethylation leads to elevated mutation rates
8. Alterations in DNA methylation: A fundamental aspect of neoplasia
9. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines
10. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines
11. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
12. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas
13. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors
14. Transcriptional silencing of cyclooxygenase-2 by hypermethylation of the 5′ CpG island in human gastric carcinoma cells
15. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression
16. Distinct mechanisms of loss of estrogen receptor α gene expression in human breast cancer: Methylation of the gene and alteration of trans-acting factors
17. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer
18. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
19. Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells
20. Cellular differentiation, cytidine analogs and DNA methylation
21. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation
22. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action
23. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine
24. CIA randomized controlled trial of subcutaneous azacitidine (Aza C) in patients with the myelodysplastic syndrome (MDS): A study of the cancer and leukemia group B (CALGB)
25. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues
26. Phase I study of 5-azacytidine (NSC-102816)
27. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer
28. Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271)
29. Phase II study of 5-azacytidine in sarcomas of bone
30. Phase II study of 5-azacytidine in solid tumors
31. Phase II study of 5-azacytidine in solid tumors
32. Twice weekly 5-azacytidine infusion in disseminated metastatic cancer: A phase II study
33. Absorption, distribution and excretion of 5-azacytidine (NSC-102816) in man
34. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816)
35. Sequential combination of pyrazofurin and 5-azacytidine in patients with acute myelocytic leukemia and carcinoma
36. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients
37. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas
38. 5-Aza-2′-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group
39. 5-aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervix
40. Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group
41. A phase II study of 5-aza-2′-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer
42. Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine
43. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer
44. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine
45. Synergistic cytotoxicity using 2′-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells
46. Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo
47. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer
48. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE)
49. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands
50. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
51. COBRA: A sensitive and quantitative DNA methylation assay
52. MethyLight: A high-throughput assay to measure DNA methylation
53. Epigenetic patterns in the progression of esophageal adenocarcinoma
54. Modified oligonucleotides as bona fide antagonists of proteins interacting with DNA. Hairpin antagonists of the human DNA methyltransferase
55. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide
56. Towards a pharmacology of DNA methylation
57. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
58. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene